ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Reprogramming the Immune Landscape of Inflammatory Breast Cancer.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Inflammatory breast cancer (IBC) is the most aggressive subtype of breast cancer, characterized by rapid progression, early metastasis, and profound therapeutic resistance. Despite advances in multimodal therapy, outcomes remain poor, emphasizing the need for novel treatment strategies. Increasing evidence reveals that IBC exhibits an immunosuppressive tumor microenvironment (TME), driven by interactions among tumor cells and TME components that promote immune evasion through cytokine signaling loops, immune checkpoint overexpression, and formation of tumor emboli that shield cancer cells from immune surveillance. Recent multi-omics and spatial transcriptomic studies reveal extensive immune heterogeneity, with both "immune-hot" and "immune-cold" niches influencing responses to immunotherapy. Clinical trials testing immune checkpoint inhibitors alone or combined with chemotherapy, antibody-drug conjugates, or targeted therapy show early promise but remain limited by small IBC cohorts and inconsistent diagnostic criteria. Integrating immune biomarkers, including PD-L1 expression, tumor mutational burden, T-cell clonality, and spatial immune signatures, may improve patient stratification and therapeutic precision. This review summarizes mechanistic and clinical insights defining IBC immunobiology, highlights barriers to durable immune activation, and outlines strategies to reprogram the TME toward an immunoactive state. Advancing combination immunotherapy and adaptive clinical trial designs through global collaboration will be essential to improve outcomes for IBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.